Market Overview:
The global lung cancer liquid biops market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of lung cancer, technological advancements in liquid biopsy methods, and rising demand for early diagnosis and treatment of lung cancer. Based on type, the global market is segmented into exosomes and RNA, CTCs and ctDNA. The exosomes and RNA segment is expected to grow at a higher CAGR during the forecast period owing to increasing use of these methods for diagnosis of various types of cancers. Based on application, the global market is segmented into hospitals and clinics, physicians'office laboratories, clinical diagnostic laboratories. The hospitalsand clinics segment accounted for majority share in 2017 owing to rising demand for early diagnosisand treatmentof various typesof cancers including lung cancer.
Product Definition:
Lung cancer liquid biopsies are a relatively new technology that uses a sample of blood or other body fluid to test for the presence of cancer cells. This type of biopsy is often used when a tumor cannot be seen on imaging scans, such as CT or MRI scans. Lung cancer liquid biopsies can help doctors determine if a person has lung cancer and can also be used to monitor the progress of treatment.
Exosomes and RNA:
Exosomes are non-cellular particles that are released by cells during intercellular communication. They can be detected in the blood and urine within a few days of being formed. Exosomes serve as an alternative source of nucleic acids and proteins, which may be useful for tissue regeneration or disease treatment depending on their concentration and type.
CTCs and ctDNA:
CTCs are cancer-associated molecular patterns that are found in malignant tumors. ctDNA is a form of CTCs and is also known as tumor DNA. It serves as a biomarker for diagnosis, prognosis, and treatment monitoring of various types of cancers including lung cancer.
Application Insights:
The clinical diagnostics segment dominated the global market in 2017. This can be attributed to factors such as rising prevalence of cancer and increasing demand for sensitive, rapid and accurate diagnostic tests. For instance, in June 2018, Quest Diagnostics acquired Med Fusion LLC to expand its laboratory business with focus on molecular testing services. The company plans to use the genetic information from Genome Institute of Medicine & Life Sciences (GIML) at Memorial Hermann Health System - one of the top hospitals in Texas -to develop new diagnostic tests for lung cancer.
Regional Analysis:
North America dominated the global market in 2017. The presence of well-established healthcare infrastructure and high adoption of liquid biopsy products by leading companies are some factors responsible for its large share. In addition, growing number of clinical trials that use liquid biopsy data to determine treatment options is expected to drive the North American regional market over the forecast period.
Asia Pacific is anticipated to grow at a lucrative rate during the forecast period owing to increasing government initiatives and awareness programs regarding lung cancer detection in emerging countries such as China and India. For instance, as part of its efforts towards improving public health, China’s Ministry of Health (MoH) launched “Healthy Lives 2020†campaign which focuses on reducing smoking prevalence among Chinese population from 30% currently down to 15% by 2020 through various interventions including advertising bans & restrictions on tobacco sales & promotion, raising taxes on cigarettes & other forms of tobacco consumption tax increases etc.).
Growth Factors:
- Increasing incidence of lung cancer
- Rising demand for personalized medicine
- Growing popularity of liquid biopsy tests
- Advances in technology and instrumentation
- Proliferation of targeted therapies
Scope Of The Report
Report Attributes
Report Details
Report Title
Lung Cancer Liquid Biops Market Research Report
By Type
Exosomes and RNA, CTCs and ctDNA
By Application
Hospitals and Clinics, Physicians'Office Laboratories, Clinical Diagnostic Laboratories
By Companies
Biocept, EntroGen, Cynvenio Biosystems, Exosome Diagnostics, F. Hoffmann-La Roche, Clearbridge BioMedics, Bio-Rad Laboratories, Agena Bioscience, Cancer Genetics, CellMax Life, Nateras, MedGenome, OncoDNA, Genomic Health, Trovagene, Fluxion Biosciences, Biodesix, Epic Sciences, Shuwen Biotech, Personal Genome Diagnostics, Predicine
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Lung Cancer Liquid Biops Market Report Segments:
The global Lung Cancer Liquid Biops market is segmented on the basis of:
Types
Exosomes and RNA, CTCs and ctDNA
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals and Clinics, Physicians'Office Laboratories, Clinical Diagnostic Laboratories
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biocept
- EntroGen
- Cynvenio Biosystems
- Exosome Diagnostics
- F. Hoffmann-La Roche
- Clearbridge BioMedics
- Bio-Rad Laboratories
- Agena Bioscience
- Cancer Genetics
- CellMax Life
- Nateras
- MedGenome
- OncoDNA
- Genomic Health
- Trovagene
- Fluxion Biosciences
- Biodesix
- Epic Sciences
- Shuwen Biotech
- Personal Genome Diagnostics
- Predicine
Highlights of The Lung Cancer Liquid Biops Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Exosomes and RNA
- CTCs and ctDNA
- By Application:
- Hospitals and Clinics
- Physicians'Office Laboratories
- Clinical Diagnostic Laboratories
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lung Cancer Liquid Biops Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lung cancer liquid biopsies are a type of medical test that uses a small amount of fluid from the lungs to look for signs of cancer. Lung cancer liquid biopsies can be used to help diagnose lung cancer and determine whether it is growing or has spread.
Some of the major companies in the lung cancer liquid biops market are Biocept, EntroGen, Cynvenio Biosystems, Exosome Diagnostics, F. Hoffmann-La Roche, Clearbridge BioMedics, Bio-Rad Laboratories, Agena Bioscience, Cancer Genetics, CellMax Life, Nateras, MedGenome, OncoDNA, Genomic Health, Trovagene, Fluxion Biosciences, Biodesix, Epic Sciences, Shuwen Biotech, Personal Genome Diagnostics, Predicine.
The lung cancer liquid biops market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lung Cancer Liquid Biops Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Lung Cancer Liquid Biops Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Lung Cancer Liquid Biops Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Lung Cancer Liquid Biops Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Lung Cancer Liquid Biops Market Size & Forecast, 2020-2028
4.5.1 Lung Cancer Liquid Biops Market Size and Y-o-Y Growth
4.5.2 Lung Cancer Liquid Biops Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Exosomes and RNA
5.2.2 CTCs and ctDNA
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals and Clinics
6.2.2 Physicians'Office Laboratories
6.2.3 Clinical Diagnostic Laboratories
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lung Cancer Liquid Biops Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lung Cancer Liquid Biops Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Exosomes and RNA
9.6.2 CTCs and ctDNA
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals and Clinics
9.10.2 Physicians'Office Laboratories
9.10.3 Clinical Diagnostic Laboratories
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Exosomes and RNA
10.6.2 CTCs and ctDNA
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals and Clinics
10.10.2 Physicians'Office Laboratories
10.10.3 Clinical Diagnostic Laboratories
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Exosomes and RNA
11.6.2 CTCs and ctDNA
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals and Clinics
11.10.2 Physicians'Office Laboratories
11.10.3 Clinical Diagnostic Laboratories
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Exosomes and RNA
12.6.2 CTCs and ctDNA
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals and Clinics
12.10.2 Physicians'Office Laboratories
12.10.3 Clinical Diagnostic Laboratories
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Exosomes and RNA
13.6.2 CTCs and ctDNA
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals and Clinics
13.10.2 Physicians'Office Laboratories
13.10.3 Clinical Diagnostic Laboratories
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lung Cancer Liquid Biops Market: Competitive Dashboard
14.2 Global Lung Cancer Liquid Biops Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biocept
14.3.2 EntroGen
14.3.3 Cynvenio Biosystems
14.3.4 Exosome Diagnostics
14.3.5 F. Hoffmann-La Roche
14.3.6 Clearbridge BioMedics
14.3.7 Bio-Rad Laboratories
14.3.8 Agena Bioscience
14.3.9 Cancer Genetics
14.3.10 CellMax Life
14.3.11 Nateras
14.3.12 MedGenome
14.3.13 OncoDNA
14.3.14 Genomic Health
14.3.15 Trovagene
14.3.16 Fluxion Biosciences
14.3.17 Biodesix
14.3.18 Epic Sciences
14.3.19 Shuwen Biotech
14.3.20 Personal Genome Diagnostics
14.3.21 Predicine
